Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icatibant for Prevention of Intradialytic Hypotension
NCT05834777Phase 3Active, not recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Dec 2023
- Primary completion
- Nov 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in intradialytic hypotension (IDH) comparing Icatibant with Placebo (2 arms). Primary endpoint: Blood pressure during hemodialysis. Started Dec 2023; status: active, not recruiting.
02
Drugs
icatibant
03
Conditions
intradialytic hypotension (IDH)
Beyond the preview
Go deeper on NCT05834777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05834777.